title: Health-related quality of life in a randomized trial of antiretroviral therapy for advanced HIV disease.
abstract: OBJECTIVE
  To assess and compare alternative approaches of measuring preference-based health-related quality of life (HRQoL) in treatment-experienced HIV patients and evaluate their association with health status and clinical variables.
  
  
  METHODS
  Cross-sectional study.
  
  
  METHODS
  Twenty-eight Veterans Affairs hospitals in the United States, 13 hospitals in Canada, and 8 hospitals in the United Kingdom.
  
  
  METHODS
  Three hundred sixty-eight treatment-experienced HIV-infected patients enrolled in the Options in Management with Antiretrovirals randomized trial.
  
  
  METHODS
  Baseline sociodemographic and clinical indicators and baseline HRQoL using the Medical Outcome Study HIV Health Survey (MOS-HIV), the EQ-5D, the EQ-5D visual analog scale (EQ-5D VAS), the Health Utilities Index Mark 3 (HUI3), and standard gamble (SG) and time trade-off (TTO) techniques.
  
  
  RESULTS
  The mean (SD) baseline HRQoL scores were as follows: MOS-HIV physical health summary score 41.70 (11.16), MOS-HIV mental health summary score 44.76 (11.38), EQ-5D 0.77 (0.19), HUI3 0.59 (0.32), EQ-5D VAS 65.94 (21.71), SG 0.75 (0.29), and TTO 0.80 (0.31). Correlations between MOS-HIV summary scores and EQ-5D, EQ-5D VAS, and HUI3 ranged from 0.60 to 0.70; the correlation between EQ-5D and HUI3 was 0.73; and the correlation between SG and TTO was 0.43. Preference-based HRQoL scores were related to physical, mental, social, and overall health as measured by MOS-HIV. Concomitant medication use, CD4 cell count, and HIV viral load were related to some instruments' scores.
  
  
  CONCLUSIONS
  On average, preference-based HRQoL for treatment-experienced HIV patients was decreased relative to national norms but also highly variable. Health status and clinical variables were related to HRQoL.
authors.affiliation: Veterans Affairs Palo Alto Health Care System, Veterans Affairs Cooperative Studies Program Coordinating Center, Menlo Park, CA 94025, USA. vilija.joyce@va.gov
authors.forename: Vilija R
authors.initials: VR
authors.lastname: Joyce
authors.forename: Paul G
authors.initials: PG
authors.lastname: Barnett
authors.forename: Ahmed M
authors.initials: AM
authors.lastname: Bayoumi
authors.forename: Susan C
authors.initials: SC
authors.lastname: Griffin
authors.forename: Tassos C
authors.initials: TC
authors.lastname: Kyriakides
authors.forename: Wei
authors.initials: W
authors.lastname: Yu
authors.forename: Vandana
authors.initials: V
authors.lastname: Sundaram
authors.forename: Mark
authors.initials: M
authors.lastname: Holodniy
authors.forename: Sheldon T
authors.initials: ST
authors.lastname: Brown
authors.forename: William
authors.initials: W
authors.lastname: Cameron
authors.forename: Mike
authors.initials: M
authors.lastname: Youle
authors.forename: Mark
authors.initials: M
authors.lastname: Sculpher
authors.forename: Aslam H
authors.initials: AH
authors.lastname: Anis
authors.forename: Douglas K
authors.initials: DK
authors.lastname: Owens
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002170:Canada; D003430:Cross-Sectional Studies; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D012959:Socioeconomic Factors; D011795:Surveys and Questionnaires; D006113:United Kingdom; D014481:United States
chemical_list: D019380:Anti-HIV Agents